Home > Boards > US Listed > Biotechs > RedHill Biopharma Ltd. (RDHL)

Whew. This is either very ugly or

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
noretreat Member Profile
 
Followed By 121
Posts 11,809
Boards Moderated 0
Alias Born 01/06/10
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/3/2021 9:07:29 AM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 4/26/2021 6:31:23 AM
DSMB gives green light for RedHill Bio's late-stage opaganib study in COVID-19 Seeking Alpha - 4/9/2021 7:42:56 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/9/2021 7:04:53 AM
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue PR Newswire (US) - 4/9/2021 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/9/2021 6:04:57 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 4/8/2021 4:38:48 PM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 3/30/2021 8:01:39 AM
RedHill enters Movantik patent litigation settlement with MSN pharmaceuticals Seeking Alpha - 3/25/2021 9:36:12 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/25/2021 9:31:46 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/25/2021 9:27:56 AM
RedHill Biopharma Announces Settlement of MovantikĀ® Patent Litigation with MSN Pharmaceuticals PR Newswire (US) - 3/25/2021 9:15:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/22/2021 7:04:08 AM
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland PR Newswire (US) - 3/22/2021 7:00:00 AM
RedHill misses on revenue Seeking Alpha - 3/18/2021 7:02:45 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/18/2021 7:02:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/18/2021 7:00:49 AM
RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights PR Newswire (US) - 3/18/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/11/2021 7:01:12 AM
RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18,... PR Newswire (US) - 3/11/2021 7:00:00 AM
RedHill to Present at Upcoming Conferences in March PR Newswire (US) - 3/5/2021 7:00:00 AM
RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares PR Newswire (US) - 3/4/2021 12:10:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 9:19:53 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/3/2021 4:32:44 PM
ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home P... PR Newswire (US) - 3/2/2021 9:06:00 AM
noretreat   Thursday, 03/12/20 10:04:15 PM
Re: None
Post # of 2899 
Whew. This is either very ugly or a great buy

No Retreat ... No Surrender
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences